These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 19929837)

  • 21. Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening.
    Paricharak S; Méndez-Lucio O; Chavan Ravindranath A; Bender A; IJzerman AP; van Westen GJP
    Brief Bioinform; 2018 Mar; 19(2):277-285. PubMed ID: 27789427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
    Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
    Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fragment-Based Drug Discovery for RNA Targets.
    Lundquist KP; Panchal V; Gotfredsen CH; Brenk R; Clausen MH
    ChemMedChem; 2021 Sep; 16(17):2588-2603. PubMed ID: 34101375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficiency of hit generation and structural characterization in fragment-based ligand discovery.
    Larsson A; Jansson A; Åberg A; Nordlund P
    Curr Opin Chem Biol; 2011 Aug; 15(4):482-8. PubMed ID: 21724447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular complexity and fragment-based drug discovery: ten years on.
    Leach AR; Hann MM
    Curr Opin Chem Biol; 2011 Aug; 15(4):489-96. PubMed ID: 21665521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fragment-based drug discovery and its application to challenging drug targets.
    Price AJ; Howard S; Cons BD
    Essays Biochem; 2017 Nov; 61(5):475-484. PubMed ID: 29118094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Designing a diverse high-quality library for crystallography-based FBDD screening.
    Tounge BA; Parker MH
    Methods Enzymol; 2011; 493():3-20. PubMed ID: 21371585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medicinal chemistry inspired fragment-based drug discovery.
    Lanter J; Zhang X; Sui Z
    Methods Enzymol; 2011; 493():421-45. PubMed ID: 21371600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening Library Design.
    Ashenden SK
    Methods Enzymol; 2018; 610():73-96. PubMed ID: 30390806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How Size Matters: Diversity for Fragment Library Design.
    Shi Y; von Itzstein M
    Molecules; 2019 Aug; 24(15):. PubMed ID: 31387220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using DNA-encoded libraries of fragments for hit discovery of challenging therapeutic targets.
    Zhao G; Zhu M; Li Y; Zhang G; Li Y
    Expert Opin Drug Discov; 2024 Jun; 19(6):725-740. PubMed ID: 38753553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
    Hennig M; Ruf A; Huber W
    Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Native State Mass Spectrometry, Surface Plasmon Resonance, and X-ray Crystallography Correlate Strongly as a Fragment Screening Combination.
    Woods LA; Dolezal O; Ren B; Ryan JH; Peat TS; Poulsen SA
    J Med Chem; 2016 Mar; 59(5):2192-204. PubMed ID: 26882437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Applications of Solution NMR in Drug Discovery.
    Shi L; Zhang N
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ligand specificity, privileged substructures and protein druggability from fragment-based screening.
    Barelier S; Krimm I
    Curr Opin Chem Biol; 2011 Aug; 15(4):469-74. PubMed ID: 21411360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular-Simulation-Driven Fragment Screening for the Discovery of New CXCL12 Inhibitors.
    Martinez-Rosell G; Harvey MJ; De Fabritiis G
    J Chem Inf Model; 2018 Mar; 58(3):683-691. PubMed ID: 29481075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PAIN(S) relievers for medicinal chemists: how computational methods can assist in hit evaluation.
    Stork C; Kirchmair J
    Future Med Chem; 2018 Jul; 10(13):1533-1535. PubMed ID: 29956552
    [No Abstract]   [Full Text] [Related]  

  • 39. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electron density guided fragment-based drug design--a lead generation example.
    Abad MC; Gibbs AC; Zhang X
    Methods Enzymol; 2011; 493():487-508. PubMed ID: 21371603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.